Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The closing price of CorMedix Inc (NASDAQ: CRMD) was $12.22 for the day, down -1.69% from the previous closing price of $12.43. In other words, the price has decreased by -$1.69 from its previous closing price. On the day, 1.11 million shares were traded.
Ratios:
Our analysis of CRMD’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.99 and its Current Ratio is at 4.21. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Leerink Partners on March 07, 2025, initiated with a Outperform rating and assigned the stock a target price of $18.
On January 13, 2025, D. Boral Capital started tracking the stock assigning a Buy rating and target price of $15.
On August 26, 2024, Rodman & Renshaw started tracking the stock assigning a Buy rating and target price of $13.Rodman & Renshaw initiated its Buy rating on August 26, 2024, with a $13 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Oct 31 ’24 when Mistry Erin bought 1,500 shares for $9.99 per share. The transaction valued at 14,985 led to the insider holds 52,011 shares of the business.
Hurlburt Elizabeth sold 140,027 shares of CRMD for $1,565,670 on Nov 14 ’24. The EVP now owns 45,397 shares after completing the transaction at $11.18 per share. On Nov 14 ’24, another insider, Hurlburt Elizabeth, who serves as the Officer of the company, bought 140,027 shares for $11.12 each.
Valuation Measures:
As of this moment, CorMedix’s Price-to-Earnings (P/E) ratio for their current fiscal year is 54.21, and their Forward P/E ratio for the next fiscal year is 8.10. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.04 while its Price-to-Book (P/B) ratio in mrq is 7.20.
Stock Price History:
Over the past 52 weeks, CRMD has reached a high of $13.85, while it has fallen to a 52-week low of $3.61. The 50-Day Moving Average of the stock is 30.19%, while the 200-Day Moving Average is calculated to be 30.76%.
Shares Statistics:
A total of 67.71M shares are outstanding, with a floating share count of 65.96M. Insiders hold about 2.75% of the company’s shares, while institutions hold 34.65% stake in the company.
Earnings Estimates
Current recommendations for the stock of the company come from 6.0 analysts. The consensus estimate for the next quarter is $0.18, with high estimates of $0.33 and low estimates of $0.07.
Analysts are recommending an EPS of between $1.18 and $0.5 for the fiscal current year, implying an average EPS of $0.8. EPS for the following year is $1.51, with 6.0 analysts recommending between $2.12 and $0.81.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 6 analysts. It ranges from a high estimate of $31.2M to a low estimate of $28M. As of the current estimate, CorMedix Inc’s year-ago sales were $806.12kFor the next quarter, 6 analysts are estimating revenue of $35.75M. There is a high estimate of $46.53M for the next quarter, whereas the lowest estimate is $29.3M.
A total of 6 analysts have provided revenue estimates for CRMD’s current fiscal year. The highest revenue estimate was $172.91M, while the lowest revenue estimate was $128.08M, resulting in an average revenue estimate of $144.23M. In the same quarter a year ago, actual revenue was $43.47MBased on 6 analysts’ estimates, the company’s revenue will be $221.41M in the next fiscal year. The high estimate is $279.3M and the low estimate is $150.2M.
